PROCY STATEMENT

Company

Actinium Pharmaceuticals, Inc.

Filed

November 21, 2022

Period of Report

December 8, 2022

Accession Number

0001213900-22-074269

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →